NCT01212432UnknownPhase 2
Daptomycin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-venous Hemodiafiltration, a Dose Finding Study
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Sponsor
- University of Zurich
- Enrollment
- 15
- Locations
- 1
- Primary Endpoint
- Pharmacokinetics
Study Overview
Brief Summary
Daptomycin kinetics in CRRT
- Trial with medicinal product
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 90 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Pharmacokinetics
Time Frame: 2011
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 4
Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD)Critically IllHemodialysisNCT00663403University of Michigan8
Unknown
Phase 2
Daptomycin Pharmacokinetics in Continuous Veno-venous HemodiafiltrationBacteremiaNCT01171547University of Zurich15
Completed
Phase 1
Safety Study to Evaluate Daptomycin in Non-infected Adults Who Are Either on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis (MK-3009-021)End-Stage Renal DiseaseNCT00490737Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)12
Completed
Phase 3
Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass SurgeryLate Effects of SurgeryStaphylococcus AureusSurgical Site InfectionNCT00701636Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center30
Completed
Not Applicable
Pharmacokinetic Variability of Daptomycin During Prolonged Therapy for Bone and Joint InfectionsBone and Joint InfectionPatient Treated by DaptomycinNCT03209921Hospices Civils de Lyon23